Tasly 2025 Annual Report Interpretation: Non-GAAP Net Profit Declined 23.59%, Financing Cash Flow Net Amount Reduced Loss by 84.92%

Core Profitability Metrics: Net Profit Growth Relies on Non-Recurring Gains, Core Profit Under Pressure

In 2025, Tasly achieved operating revenue of 8.236 billion yuan, down 3.08% year-over-year; net profit attributable to shareholders of the listed company was 1.105 billion yuan, up 15.63%; non-recurring net profit was 791 million yuan, a sharp decrease of 23.59% year-over-year.

From the perspective of profit quality, the growth in net profit mainly benefited from non-recurring gains and losses, which reached 314 million yuan during the reporting period, turning losses into profits significantly compared to the same period last year, mainly driven by fair value changes of financial assets. The decline in non-recurring net profit is primarily due to price reductions in centralized procurement, leading to lower gross margins in the pharmaceutical industry. Revenue in the pharmaceutical sector decreased by 2.54% year-over-year, with gross margin decreasing by 0.71 percentage points to 70.37%.

Per share earnings, basic earnings per share were 0.74 yuan, up 15.63%, consistent with net profit growth; non-recurring per share earnings were 0.53 yuan, down 23.19%, reflecting a decline in core business profitability.

Cost Control: R&D Expenses Significantly Reduced, Selling Expenses Slightly Decreased

Total operating expenses for 2025 were 397 million yuan, down 6.41% year-over-year, mainly due to a significant reduction in R&D expenses.

Selling Expenses: Slight Decrease of 0.55%, Structural Optimization

Selling expenses amounted to 2.972 billion yuan, a slight decrease of 0.55%. Among them, staff costs increased by 14.57% to 1.029 billion yuan, while marketing promotion expenses decreased by 9.39% to 1.802 billion yuan, indicating the company has reduced traditional marketing investments and shifted toward personnel-driven refined marketing.

Management Expenses: Down 3.23%, Efficiency Improvement

Management expenses were 334 million yuan, down 3.23%, mainly due to reductions in office communication, travel, and service fees, reflecting cost-saving and efficiency gains in internal management.

Financial Expenses: Narrowed Loss, Reduced Interest Payments

Financial expenses were a loss of 23.2569 million yuan, a 7.63% increase in loss (loss narrowed). This was mainly due to interest expenses decreasing from 61.282 million yuan to 32.495 million yuan, and interest income dropping from 91.05 million yuan to 58.341 million yuan, easing overall financial cost pressure.

R&D Expenses: Decreased by 17.40%, Capitalization Rate Increased

R&D expenses totaled 686 million yuan, a significant decrease of 17.40%. However, capitalized R&D investments reached 160 million yuan, with the capitalization rate increasing from 20…29% to 18.90%. The reduction in R&D investment mainly reflects decreases in technical testing costs and material consumption, but key capitalized projects such as the international clinical research of Fufang Danshen Droplet and new anti-tumor drugs are still progressing. During the reporting period, development expenditure impairment provisions increased by 53.1 million yuan, indicating some R&D projects did not meet expectations.

R&D Personnel: Stable Scale, Optimized Structure

As of the end of 2025, the company had 1,345 R&D personnel, accounting for 12.70% of total staff, roughly stable from the previous year. In terms of educational background, there are 55 PhDs or above, 410 master’s degree holders, and 760 undergraduates, with high-education personnel accounting for 89.6%, further improving the professional quality of the R&D team. Age-wise, 40.9% are aged 30-40, forming the core R&D force, with a relatively young and experienced team.

Cash Flow: Operating Cash Declines, Investment and Financing Cash Flows Reduce Losses

Operating Cash Flow: Down 29.28%, Payment Pressure Emerges

Net cash flow from operating activities was 1.425 billion yuan, a decrease of 29.28%. This was mainly due to cash received from sales dropping from 9.255 billion yuan to 8.156 billion yuan. Although cash paid for purchasing goods and employee payments decreased, the decline was less than revenue, reflecting slower product collection under centralized procurement, leading to a decline in operating cash flow quality.

Investing Cash Flow: Reduced Losses by 52.55%, Investment Scale Shrinks

Net cash flow from investing activities was -445.6 million yuan, a reduction of 52.55% in losses. This was mainly because, compared to the high bill guarantees last year, cash recovered from investments decreased from 7.237 billion yuan to 5.93 billion yuan, and cash paid for investments decreased from 7.524 billion yuan to 6.35 billion yuan. The scale of financial asset investments shrank, and investment losses decreased.

Financing Cash Flow: Reduced Losses by 84.92%, Debt Repayment Pressure Eases

Net cash flow from financing activities was -370 million yuan, a significant reduction of 84.92% in losses. This was mainly because last year’s debt repayment and acceptance payments were large; this year, debt repayment cash decreased from 2.511 billion yuan to 1.51 billion yuan, and cash received from borrowings decreased from 1.451 billion yuan to 884 million yuan, significantly easing financing cash outflows.

Potential Risks: Industry Policies, R&D, and Cost Pressures Persist

Pharmaceutical Industry Policy Risks

Deepening reforms of medical insurance payment methods (DRG/DIP), dynamic adjustments to the medical insurance catalog emphasizing clinical value and cost-effectiveness, and ongoing volume-based procurement exert downward pressure on prices. Additionally, stricter regulation of marketing compliance, such as the “Guidelines for Preventing Commercial Bribery in Pharmaceutical Companies,” increases compliance costs.

New Product Development Risks

Drug R&D involves long cycles, high investment, and high uncertainty. The company currently has 31 innovative drugs in development, but some projects, such as MKT brain and neurosurgery patents, have impairment provisions. The risk of R&D failure or delays remains. Increasing competition in innovative drugs and potential homogenization may reduce project commercialization value.

Raw Material Price Risks

Although the prices of traditional Chinese medicinal herbs are in a downward cycle, some rare varieties like agarwood still face supply pressures. The company needs to maintain strategic reserves to cope with price fluctuations. If prices rebound, production costs will rise directly.

Operational Management Risks

With numerous subsidiaries across different regions, management complexity increases. Accounts receivable grew by 43.36% to 1.118 billion yuan, raising concerns over credit management and collection risks.

Executive Compensation: Differentiated Pay for Core Management

During the reporting period, Chairman Zhou Hui did not receive a salary, with remuneration paid by affiliated party China Resources Sanjiu. General Manager Cai Jinyong received pre-tax compensation of 1.839 million yuan; Vice President Yu Jie, the highest paid at 2.486 million yuan, also serves as the Board Secretary; CFO Wei Jie received 1.559 million yuan pre-tax. Overall, executive compensation is linked to company performance and reflects role responsibilities.

Click to view the original announcement>>

Disclaimer: The market involves risks; investment should be cautious. This article is automatically generated by an AI model based on third-party data and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to official announcements for accuracy. For questions, contact biz@staff.sina.com.cn.